Chimerix names Ernest Mario as next chairman of the board
Mario previously held positions as CEO, chairman and director of multiple pharmaceutical companies. Mario is currently the CEO and chairman of Capnia, a privately held pharmaceutical company.
"Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms," Kenneth I. Moch, the president and CEO of Chimerix, said. "His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase III clinical development and commercial launch."
Mario previously worked for Glaxo Holdings, plc, ALZA, Reliant Pharmaceuticals and Pharmaceutical Product Development Inc.
"I am thrilled to be joining a Chimerix team that has already made great strides to validate its science and IP by advancing CMX001 into Phase III and by licensing CMX157 to Merck," Mario said. "I look forward to working with Ken, the board and the entire Chimerix team to build upon the company's success to date and to help bring CMX001 to patients who might benefit from it worldwide."
CMX001 and CMX157 are clinical-stage lipid acyclic nucleoside phosphonates. In Phase II clinical trials, CMX001 was found to block replication of double-stranded DNA viruses such as herpes simplex. CMX157 is a product candidate in development for the treatment of HIV. The candidate was licensed to Merck in July.